Carregant...
Development of Antibody‐Directed Therapies: Quo Vadis?
Less is more: The efficacy of antibody–drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.[Image: see text]
Guardat en:
| Publicat a: | Angew Chem Int Ed Engl |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5838556/ https://ncbi.nlm.nih.gov/pubmed/29341367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.201712185 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|